PE20141568A1 - Anticuerpos humanizados que reconocen la alfa-sinucleina - Google Patents

Anticuerpos humanizados que reconocen la alfa-sinucleina

Info

Publication number
PE20141568A1
PE20141568A1 PE2014000613A PE2014000613A PE20141568A1 PE 20141568 A1 PE20141568 A1 PE 20141568A1 PE 2014000613 A PE2014000613 A PE 2014000613A PE 2014000613 A PE2014000613 A PE 2014000613A PE 20141568 A1 PE20141568 A1 PE 20141568A1
Authority
PE
Peru
Prior art keywords
sinuclein
seq
humanized antibodies
recognize alpha
refers
Prior art date
Application number
PE2014000613A
Other languages
English (en)
Inventor
Jose Saldanha
Tarlochan S Nijjar
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of PE20141568A1 publication Critical patent/PE20141568A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Abstract

SE REFIERE A UN ANTICUERPO QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA MADURA QUE COMPRENDE LAS TRES CDRS DE KABAT DE LA SEQ ID NO:11, Y SIENDO EL 90% IDENTICA A LA SEQ ID NO: 11, Y UNA CADENA LIGERA QUE COMPRENDE LAS TRES CDRS DE KABAT DE LA SEQ ID NO: 4, Y SIENDO EL 90% IDENTICA A LA SEQ ID NO: 4. DICHOS ANTICUERPOS SE UNEN A LA ALFA SINUCLEINA HUMANA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA LA INMUNOTERAPIA DE LA ENFERMEDAD DE CUERPOS DE LEWY.
PE2014000613A 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina PE20141568A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553131P 2011-10-28 2011-10-28
US201261711208P 2012-10-08 2012-10-08

Publications (1)

Publication Number Publication Date
PE20141568A1 true PE20141568A1 (es) 2014-11-21

Family

ID=48168610

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000613A PE20141568A1 (es) 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina

Country Status (31)

Country Link
US (7) US8609820B2 (es)
EP (2) EP2771031B1 (es)
JP (4) JP5775974B2 (es)
KR (1) KR101600733B1 (es)
CN (2) CN104334184B (es)
AU (3) AU2012328530A1 (es)
BR (1) BR112014010198B1 (es)
CA (1) CA2853531C (es)
CL (1) CL2014001073A1 (es)
CO (1) CO7020875A2 (es)
CY (1) CY1120398T1 (es)
DK (2) DK2771031T3 (es)
ES (2) ES2937409T3 (es)
FI (1) FI3378535T3 (es)
HK (3) HK1201450A1 (es)
HR (2) HRP20230065T1 (es)
HU (2) HUE061978T2 (es)
IL (2) IL232264B (es)
LT (2) LT2771031T (es)
MX (2) MX370234B (es)
MY (1) MY165038A (es)
PE (1) PE20141568A1 (es)
PL (2) PL3378535T3 (es)
PT (2) PT2771031T (es)
RS (2) RS63930B1 (es)
RU (1) RU2743738C2 (es)
SG (1) SG11201401857WA (es)
SI (2) SI3378535T1 (es)
UA (1) UA116194C2 (es)
WO (1) WO2013063516A1 (es)
ZA (1) ZA201403864B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2015075635A2 (en) * 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
PE20190440A1 (es) 2016-06-02 2019-03-27 Medimmune Ltd Anticuerpos a la alfa-sinucleina y usos de los mismos
US20180328943A1 (en) * 2016-09-30 2018-11-15 Enzo Biochem, Inc. Immunomodulatory compositions and methods of use thereof
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
WO2018102763A1 (en) 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11220538B2 (en) 2017-05-01 2022-01-11 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
EP3672635A4 (en) 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN, AND METHODS USING THEM
CN116731173A (zh) * 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
CN112839710A (zh) 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
PE20220516A1 (es) * 2019-06-14 2022-04-07 Abl Bio Inc ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO
IL296664A (en) 2020-04-24 2022-11-01 Hoffmann La Roche Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN112710850A (zh) * 2020-12-29 2021-04-27 苏州百志生物科技有限公司 一种检测人体液中α-突触核蛋白含量的试剂盒
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
ATE490518T1 (de) 1999-02-05 2010-12-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zum wiederauffinden von texturbildern
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
CA2485342A1 (en) 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
EP1589033A4 (en) * 2003-01-22 2006-04-12 Takeda Pharmaceutical ANTIBODY AND ITS USE
RU2332986C2 (ru) 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) * 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP1697741A4 (en) 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
US7022550B2 (en) 2004-04-07 2006-04-04 Gelcore Llc Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
EP1915177A4 (en) * 2005-07-19 2011-08-31 Univ Rochester ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
AR062065A1 (es) * 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PT2126093E (pt) 2007-03-02 2012-12-03 Boehringer Ingelheim Pharma Melhoramento da produção de proteínas
US20100260766A1 (en) 2007-03-22 2010-10-14 Arvind Srivastava Stable antibody formulations
RS53402B (en) * 2007-03-22 2014-10-31 Genentech, Inc. APPLICATION OF APOPTOTIC ANTI-IGE ANTIBODIES FOR MEMBRANE IGE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
MX2010006395A (es) 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.
NZ586875A (en) 2007-12-28 2012-10-26 Elan Pharm Inc Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide
JP5747414B2 (ja) * 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
PL2949666T3 (pl) * 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
ES2668079T3 (es) 2009-07-28 2018-05-16 Shire Human Genetic Therapies Composiciones y métodos para tratar la enfermedad de Gaucher
PL214940B1 (pl) 2009-07-31 2013-09-30 Lozano Platonoff Alberto Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20130116413A1 (en) 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
KR101846590B1 (ko) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
CN103153331B (zh) 2010-07-15 2017-03-22 亚德赫伦医疗公司 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法
JP6023715B2 (ja) 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
CA2825791A1 (en) 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
US8619359B2 (en) 2011-04-27 2013-12-31 Howard Letovsky Electronic microscope filter
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
AU2012272815B2 (en) 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
EA037797B1 (ru) 2011-10-25 2021-05-21 Протена Байосайенсиз Лимитед Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
JP5775974B2 (ja) 2011-10-28 2015-09-09 プロセナ バイオサイエンシーズ リミテッド アルファシヌクレインを認識するヒト化抗体
CN108704132A (zh) 2011-10-31 2018-10-26 弗·哈夫曼-拉罗切有限公司 抗体制剂
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
RS58928B1 (sr) 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
RU2016101137A (ru) 2018-11-16
CA2853531C (en) 2020-03-10
MX370234B (es) 2019-12-06
AU2012328530A1 (en) 2014-06-26
LT2771031T (lt) 2018-08-27
MX2014005038A (es) 2015-03-09
AU2016202622A1 (en) 2016-05-19
JP2018046836A (ja) 2018-03-29
CY1120398T1 (el) 2019-07-10
JP2015502341A (ja) 2015-01-22
HUE037811T2 (hu) 2018-09-28
SI3378535T1 (sl) 2023-04-28
EP3378535A1 (en) 2018-09-26
PL3378535T3 (pl) 2023-05-08
RU2014121325A (ru) 2015-12-10
US20200024336A1 (en) 2020-01-23
UA116194C2 (uk) 2018-02-26
NZ625624A (en) 2016-06-24
BR112014010198A2 (pt) 2018-08-07
SG11201401857WA (en) 2014-09-26
HK1206637A1 (en) 2016-01-15
JP2015232002A (ja) 2015-12-24
IL232264B (en) 2020-02-27
IL232264A0 (en) 2014-06-30
AU2017276296A1 (en) 2018-01-18
CN107880123A (zh) 2018-04-06
US11345749B2 (en) 2022-05-31
US20180201669A1 (en) 2018-07-19
ZA201403864B (en) 2015-08-26
RS57315B1 (sr) 2018-08-31
JP6234511B2 (ja) 2017-11-22
RU2743738C2 (ru) 2021-02-25
LT3378535T (lt) 2023-02-27
US20140275495A1 (en) 2014-09-18
HRP20180728T1 (hr) 2018-07-27
ES2937409T3 (es) 2023-03-28
SI2771031T1 (en) 2018-08-31
PT3378535T (pt) 2023-02-06
HK1201450A1 (en) 2015-09-04
AU2017276296B2 (en) 2020-01-16
FI3378535T3 (fi) 2023-04-12
DK3378535T3 (da) 2023-01-30
EP2771031B1 (en) 2018-04-18
CL2014001073A1 (es) 2014-12-19
HRP20230065T1 (hr) 2023-03-03
IL272615B (en) 2022-04-01
DK2771031T3 (en) 2018-05-28
BR112014010198B1 (pt) 2022-12-06
US20220411486A1 (en) 2022-12-29
WO2013063516A1 (en) 2013-05-02
KR20140081898A (ko) 2014-07-01
RS63930B1 (sr) 2023-02-28
CA2853531A1 (en) 2013-05-02
US9556259B2 (en) 2017-01-31
CO7020875A2 (es) 2014-08-11
US10723792B2 (en) 2020-07-28
KR101600733B1 (ko) 2016-03-09
EP3378535B1 (en) 2023-01-04
PL2771031T3 (pl) 2018-09-28
US9884906B2 (en) 2018-02-06
US8609820B2 (en) 2013-12-17
HUE061978T2 (hu) 2023-09-28
RU2016101137A3 (es) 2020-01-09
EP2771031A4 (en) 2015-03-18
HK1252895A1 (zh) 2019-06-06
MX2019014658A (es) 2020-02-07
MY165038A (en) 2018-02-28
US20210040188A1 (en) 2021-02-11
AU2016202622B2 (en) 2017-09-14
JP6592059B2 (ja) 2019-10-16
US10450369B2 (en) 2019-10-22
US20130108546A1 (en) 2013-05-02
EP2771031A1 (en) 2014-09-03
JP2016208981A (ja) 2016-12-15
IL272615A (en) 2020-03-31
PT2771031T (pt) 2018-05-24
US20170240621A1 (en) 2017-08-24
JP5960328B2 (ja) 2016-08-02
JP5775974B2 (ja) 2015-09-09
ES2669395T3 (es) 2018-05-25
CN104334184A (zh) 2015-02-04
CN104334184B (zh) 2017-12-29

Similar Documents

Publication Publication Date Title
PE20141568A1 (es) Anticuerpos humanizados que reconocen la alfa-sinucleina
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20140247A1 (es) Anticuerpos anti-cd38
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20141017A1 (es) Anticuerpos del cea
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
PE20190261A1 (es) Anticuerpos que reconocen tau
PE20190208A1 (es) Anticuerpos que reconocen tau
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
AR109715A1 (es) Anticuerpos anti-cd27
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
PE20081478A1 (es) Anticuerpos cd44
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
PE20131209A1 (es) Anticuerpos anti-fap
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20142407A1 (es) Formulacion de anticuerpos
PE20142167A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
AR084315A1 (es) Anticuerpos anti-notch1
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados

Legal Events

Date Code Title Description
FC Refusal